Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
He has been prescribed an ICS/LABA regimen and is at risk of exacerbation, defined as:
- A worsening of symptoms, or
- Has a history of an exacerbation, treated with antibiotics or oral corticosteroids, in the past 12 months
The impact of COPD on patients – can TRELEGY Ellipta help?
Patients with COPD who are at risk of exacerbation despite treatment with and ICS/LABA or LAMA/LABA regimen, may have characteristics like John (below) and could experience a similar impact on their everyday lives. Explore how TRELEGY Ellipta could help.1
Meet John a patient with COPD treated with a TWICE-DAILY ICS/LABA
Symptomatic with COPD
Ongoing breathlessness
Cough
At risk of exacerbation
Despite being on maintenance treatment with an ICS/LABA regimen, his day-to-day life is impacted by worsening symptoms, such as:2
- Shortness of breath
- Wheezing
- Chest tightness
- Cough and sputum
This means that John could start to miss social events with friends, struggle to fix his car or have difficulty walking to the shops.3
John is not alone
Over 50% of patients treated with COPD maintenance therapies, including ICS/LABA, continue to suffer from breathlessness.4 Symptomatic patients like John could be at increased risk of exacerbation.
*An analysis of a cohort of patients with COPD within the UK Clinical Practice Research Datalink who initiated treatment with a LAMA, LABA or combination of LAMA/LABA or ICS/LABA (n=63,900). Data on exacerbations were available for all patients. Defined as at least 1 hospitalisation and/or at least 2 non-hospitalised exacerbations4
Spotting the Risk: Identifying COPD patients at risk of exacerbation*
This video will guide you to identify COPD patients who are at risk of exacerbation*.
Trelegy prescribing information and adverse event reporting information
POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000
*with worsening of symptoms, or a history of an exacerbation, treated with antibiotics or oral corticosteroids, in the past 12 months.
PM-IE-FVU-WCNT-230007 | May 2023
Spotting the Risk: Consequences of delayed treatment for COPD patients
This video aims to explain to HCPs the burden of COPD for patients at risk of exacerbation* who are not adequately treated with ICS/LABA , and reinforce the urgency to optimize treatment early with triple therapy.
Trelegy prescribing information and adverse event reporting information
POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000
*with worsening of symptoms, or a history of an exacerbation, treated with antibiotics or oral corticosteroids, in the past 12 months.
PM-IE-FVU-WCNT-230011 | May 2023
Spotting the Risk: Why Trelegy for COPD patients at risk of exacerbation*?
This video will guide you through why Trelegy Ellipta is beneficial for COPD patients at risk of exacerbation*
Trelegy prescribing information and adverse event reporting information
POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000
*with worsening of symptoms, or a history of an exacerbation, treated with antibiotics or oral corticosteroids, in the past 12 months.
PM-IE-FVU-WCNT-230003 | Date of Preparation: April 2023
It is important to reduce exacerbations. Even a single exacerbation can lead to poorer outcomes for patients with COPD5-7
~40% faster decline in lung function vs. no exacerbation*5
2x increased risk of myocardial infarction in 1–5 days after exacerbation**6
55% risk of death within 5 years following a hospitalised exacerbation†7
*Post hoc analysis of the 3-year Toward a Revolution in COPD Health (TORCH) study in patients with moderate or severe COPD. The primary endpoint did not reach statistical significance. Data shown compared patients with 0–1 moderate/severe exacerbations per annum vs. 0 exacerbations per annum
**Data analysed from 25,857 patients with COPD entered in The Health Improvement Network database in the UK. Exacerbations were defined using a healthcare use definition of prescription of oral corticosteroids >20 mg/d and/or selected oral antibiotics. There was a 2.27-fold (95% CI: 1.1–4.7; p=0.03) increased risk of MI during the 5-day period post exacerbation
†89 patients (29.3%) with 1 to >3 exacerbations were admitted to hospital at least once during 1998. Mortality in this group after 60 months was 55.2%
TRELEGY Ellipta quick links
Get started with Trelegy Ellipta
Footnotes
BD, twice daily; CI, confidence interval; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in one second; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; MI, myocardial infarction; mMRC, modified Medical Research Council; OD, once daily; QoL, quality of life
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA1
References
- TRELEGY Ellipta SmPC. Available at www.medicines.ie. Accessed April 2024.
- Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD). 2024. Available at: https://goldcopd.org/2024-gold-report/ (Accessed April 2024).
- Kessler R et al. Eur Respir J 2011; 37:264–272.
- Rebordosa C et al. Pharmacoepidemiol Drug Saf 2019; 28:126–133, including supplementary material.
- Celli B et al. Am J Respir Crit Care Med 2008; 178:332–338.
- Donaldson GC et al. Chest 2010; 137:1091–1097.
- Soler-Cataluna JJ et al. Thorax 2005; 60:925–931.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trelegy is a registered trademark of the GlaxoSmithKline group of companies.
TRELEGY Ellipta was developed in collaboration with
Last Updated: April 2024 PM-IE-FVU-WCNT-240004
